Spider-Man swings in China. Hollywood should not read too much into it

SPIDER-MAN'S triumphant opening in China has drawn excited headlines declaring Hollywood's resurgence in the world's second-largest film market. The film earned $121m in its Chinese opening weekend, with local analysts projecting a full run of $250m or more. That is a formidable number. But a single hit in a shrinking market is not a trend. It is more like a lighthouse in a fog.

The structural story is the opposite of revival. China's entire theatrical market is weaker: total ticket revenue during the first six days of the Lunar New Year holiday fell by 38.6% from 2025 to $715m, as the Hollywood Reporter reported in February. The market that once accounted for 15-20% of a global blockbuster's take has become unreliable, unpredictable, and politically conditioned.

To be sure, Spider-Man: Brand New Day is no ordinary film. It opened to $927m worldwide. Its domestic opening of $355m was just $2m short of the record domestic debut set by Avengers: Endgame in 2019. Its China performance is the biggest for a Spider-Man film in the territory and a rare bright spot in a landscape littered with flops. Only 10 American films have crossed $100m at the Chinese box office over the past five years combined; in 2019 alone, nine did. The outlier is Disney's Zootopia 2, which earned a record $650m in 2025 - a result that analysts at CNBC warn should not be extrapolated into a general recovery thesis.

The reason for the broader decline is not hard to see. It is institutional, not artistic.

China's film distribution system is controlled by the state in every direction that matters. The China Film Administration, a government body, decides which foreign films are released, when they are released, and whether they are released at all. Only two state-owned firms - China Film Group and Huaxia Film Distribution Company - are legally permitted to import and distribute foreign films. Foreign companies cannot distribute their own products. The country maintains an official quota of 34 foreign revenue-sharing films per year, though this number is never binding in practice because the authorities can simply withhold approval. Revenue-sharing terms nominally allow foreign producers to keep 25% of domestic receipts, but in practice payments from China are often small, delayed, and opaque.

This is not a free market with a quota. It is a distribution system with levers. And Beijing has been turning them. In April 2025, the China Film Administration announced it would "moderately reduce the number of American films imported", following President Trump's escalation of tariffs on Chinese goods to 125%. The Film Administration called the tariff action "wrong" and warned it would reduce Chinese audiences' favourability towards American films. The 2012 memorandum of understanding between the two countries, which had guaranteed the 34-film quota in exchange for higher revenue shares, expired in 2017 and was never renewed. Negotiations have been described as on-again, off-again. China, which has little incentive to concede, is in no hurry.

The incentive structure is clear. The Film Administration controls the supply of foreign entertainment as both cultural policy and bargaining chip. When domestic films are performing well, it tightens access for Hollywood. When the calendar is thin and cinemas need product, it opens the tap. A professor of film studies at the University of Virginia, Aynne Kokas, told CNBC that the bureau "will turn on and off the levers of distribution based on the needs of the market." The market in question is not a neutral mechanism. It is an instrument of state capacity.

Spider-Man's success in China does not contradict this. It fits within it. The film is apolitical, visually spectacular, and backed by a franchise with global recognition - precisely the profile that tends to survive Chinese screening. Distribution experts note that action spectacles, animation and franchise sequels fare best; films that require nostalgia (Star Wars, Super Mario) or contain material the authorities might find contentious tend to struggle. Spider-Man ticks all the right boxes. Its greenlight was as much about risk management as audience demand.

The deeper question is what studios should do with this information. The tempting conclusion is that a big-enough hit proves the market is still worth pursuing. The trouble is that this reasoning ignores the asymmetry of risk. A $250m haul in China would be transformative for many films, but most American releases do not earn anywhere near that. The past five years' combined tally of 10 films above $100m, against the 9 in 2019 alone, is not a distribution with a fat tail. It is a distribution with no tail. Studios continue to launch titles in China because the upside on a hit is large and the cost of a missed flop is small. That is rational for any individual release. It does not mean the aggregate strategy is sound.

There is also the second-order effect that most trade reporting overlooks: the Chinese market's weakness feeds back into American production incentives. When China was reliably profitable, studios had reason to build films with Chinese audiences in mind - casting choices, location decisions, even plot elements. That soft influence is now waning, which means American films are becoming more American. That is probably a good thing for artistic quality and a bad thing for the studios' international revenue mix. The result is a narrower, less globally optimised slate, with more concentration on properties that work in the United States and the English-speaking world.

For investors, the implication is not dramatic but directional. Sony Pictures, which releases Spider-Man under a licensing deal with Marvel Studios, stands to earn a large share of its profits from the domestic market, where the film has the biggest opening since Avengers: Endgame. The China contribution is welcome but not decisive. Disney, which retains creative control through Marvel and a smaller distribution stake, faces the broader problem of international fragmentation. Neither company's business plan can reasonably depend on a Chinese recovery. The earnings path that makes sense is one built around domestic strength, premium large-format receipts - Dolby Cinema posted record weekend earnings for Brand New Day - and streaming ancillaries.

The broader lesson for policymakers is less flattering. China's film market demonstrates how cultural distribution can be weaponised without firing a shot. The Film Administration has no need to ban Hollywood outright. It need only make approval uncertain enough that studios cannot rely on the market for planning. That is a form of soft power that costs Beijing nothing and saves Hollywood from having to think about China as a stable pillar of revenue. The 2025 announcement to reduce American imports followed tariff escalation, not vice versa. The sequencing suggests coordination, not coincidence.

American studios have spent a decade treating China as an essential international pillar. The evidence now available - a contracting overall market, a distribution system run by a single party-appointed body - suggests that pillar was always more decorative than structural. Spider-Man is a reminder that the door has not been locked. But it is also a reminder of who holds the key.